PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by

PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitor biomarker are developed for diagnosis and treatment of several diseases, and the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells which make these inhibitors an effective mode for treating cancers. PARP inhibitors are used to treat a subset of ovarian and breast cancer. There are several testing services for PARP inhibitors biomarkers which include BRCA 1 & 2 testing, HRD testing, HRR testing, and others.
Market Dynamics
Research and development of novel therapies are expected to drive the global PARP inhibitor biomarkers market during the forecast period. For instance, in June 2019, researchers at the University of Montreal Hospital Research Centre (CRCHUM) developed a two-step combination therapy for the treatment of ovarian cancer. According to the research, the combination of chemotherapy and PARP inhibitors can assist in reducing the proliferation of cancer cells and destroy them. Therefore, increasing research and development in cancer treatment is expected to offer lucrative opportunities for manufacturers to commercialize new products in the market.
Key features of the study:
This report provides in-depth analysis of the global PARP inhibitor biomarkers market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global PARP inhibitor biomarkers market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global PARP inhibitor biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor biomarkers market

Detailed Segmentation:
Global PARP Inhibitor Biomarkers Market, By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
Global PARP inhibitor Market, By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
Global PARP inhibitor Market, By Region:
North America
By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
By Country:
U.S.
Canada
Latin America
By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product & Services:
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
By Application:
Breast Cancer
Ovarian Cancer
Others (Prostate, Pancreatic, etc.)
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Myriad Genetics, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
F. Hoffmann-La Roche AG
Invitae Corporation
NeoGenomics Laboratories, Inc.
BPS Bioscience, Inc.
“*” marked represents similar segmentation in other categories in the respective section.